Prevalence and progression of pancreatic cystic precursor lesions differ between groups at high risk of developing pancreatic cancer

Pancreas

Volumn 46, Issue 1, 2017, Pages 28-34

  Konings, Ingrid C A W ^a   Harinck, Femme ^a   Poley, Jan Werner ^a   Aalfs, Cora M ^b   Van Rens, Anja ^c   Krak, Nanda C ^a   Wagner, Anja ^a   Nio, C Yung ^b   Sijmons, Rolf H ^d   Van Dullemen, Hendrik M ^e   Vleggaar, Frank P ^f   Ausems, Margreet G E M ^f   Fockens, Paul ^b   Van Hooft, Jeanin E ^b   Bruno, Marco J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

adenocarcinoma; cancer; cystic lesions; cysts; high risk individuals; pancreas; precursor lesions; surveillance

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; ENDOSCOPIC ULTRASONOGRAPHY; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PANCREAS CYST; PANCREAS RESECTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; CLINICAL TRIAL; DISEASE EXACERBATION; EARLY CANCER DIAGNOSIS; GENETICS; MIDDLE AGED; MUTATION; NETHERLANDS; PANCREAS CARCINOMA; PANCREAS TUMOR; PROCEDURES; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA;

BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; BRCA2 PROTEIN; CARCINOMA, PANCREATIC DUCTAL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NETHERLANDS; PANCREATIC CYST; PANCREATIC NEOPLASMS; PREVALENCE; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84995393662     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000725     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin. 2012; 62: 283-298
2. Coupland VH, Kocher HM, Berry DP, et al. Incidence and survival for hepatic, pancreatic and biliary cancers in England between 1998 and 2007. Cancer Epidemiol. 2012; 36: e207-e214
3. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005; 97: 1407-1427
4. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010; 46: 765-781
5. Iqbal J, Ragone A, Lubinski J, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2012; 107: 2005-2009
6. Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009; 302: 1790-1795
7. Ruijs MW, Verhoef S, Rookus MA, et al. TP53 germlinemutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet. 2010; 47: 421-428
8. Kluijt I, Cats A, Fockens P, et al. Atypical familial presentation of FAMMM syndrome with a high incidence of pancreatic cancer: case finding of asymptomatic individuals by EUS surveillance. J Clin Gastroenterol. 2009; 43: 853-857
9. de Snoo FA, Bishop DT, Bergman W, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res. 2008; 14: 7151-7157
10. Korsse SE, Harinck F, van Lier MG, et al. Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. J Med Genet. 2013; 50: 59-64
11. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004; 64: 2634-2638
12. Brune KA, Lau B, Palmisano E, et al. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst. 2010; 102: 119-126
13. Schneider R, Slater EP, Sina M, et al. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer. 2011; 10: 323-330
14. Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012; 142: 796-804
15. Kimmey MB, Bronner MP, Byrd DR, et al. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc. 2002; 56: S82-S86
16. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin GastroenterolHepatol. 2004; 2: 606-621
17. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006; 4: 766-781
18. Poley JW, Kluijt I, Gouma DJ, et al. The yield of first-Time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol. 2009; 104: 2175-2181
19. Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res. 2010; 16: 5028-5037
20. Ludwig E, Olson SH, Bayuga S, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol. 2011; 106: 946-954
21. Vasen HF, Wasser M, van Mil A, et al. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology. 2011; 140: 850-856
22. Al-Sukhni W, Borgida A, Rothenmund H, et al. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg. 2012; 16: 771-783
23. Potjer TP, Schot I, Langer P, et al. Variation in precursor lesions of pancreatic cancer among high-risk groups. Clin Cancer Res. 2013; 19: 442-449
24. de Jong K, Nio CY, Hermans JJ, et al. High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. Clin Gastroenterol Hepatol. 2010; 8: 806-811
25. Laffan TA, Horton KM, Klein AP, et al. Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol. 2008; 191: 802-807
26. Harinck F, Konings IC, Kluijt I, et al. A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. Gut. 2016; 65: 1505-1513
27. Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012; 12: 183-197
28. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016; 531: 47-52